Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 254
- Registration Number
- NCT00877890
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
The Effects of Exenatide After Gastric Restriction
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2009-03-31
- Lead Sponsor
- Advanced Specialty Care
- Target Recruit Count
- 28
- Registration Number
- NCT00872378
- Locations
- 🇺🇸
Endocrinology Services NorthWest, Bend, Oregon, United States
🇺🇸Advanced Specialty Care, Bend, Oregon, United States
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 255
- Registration Number
- NCT00870194
- Locations
- 🇲🇽
Research Site, Tampico, Mexico
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
- Conditions
- Weight LossObesity
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2019-06-04
- Target Recruit Count
- 150
- Registration Number
- NCT00856609
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States
Evaluation of Exenatide in Patients With Diabetic Neuropathy
- Conditions
- Diabetic Peripheral NeuropathyType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 46
- Registration Number
- NCT00855439
- Locations
- 🇺🇸
The University of Michigan Health System, Ann Arbor, Michigan, United States
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 54
- Registration Number
- NCT00845507
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults
- Conditions
- ObesityCardiovascular DiseaseInsulin ResistanceImpaired Glucose Tolerance
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Yale University
- Registration Number
- NCT00845559
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
- Conditions
- HealthyImpaired Glucose ToleranceType 2 Diabetes
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2018-01-18
- Target Recruit Count
- 43
- Registration Number
- NCT00845182
- Locations
- 🇺🇸
Barter Research Center, ALM VA Hospital, San Antonio, Texas, United States
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 100
- Registration Number
- NCT00835848
- Locations
- 🇩🇰
Heart Center, Rigshospitalet, Copenhagen, Denmark
Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure
- Conditions
- Heart Failure, DiastolicDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 2
- Registration Number
- NCT00799435
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.